Product Discontinuation Update: Glucagon Emergency Kit (Glucagon for injection, rDNA origin, DIN 02243297)

TORONTO, ON – August 25, 2022, Eli Lilly and Company has decided to discontinue our Glucagon Emergency Kit (Glucagon for injection, rDNA origin) from all markets. In Canada, we anticipate that the final date for the discontinuation to be the end of June 2023. We have decided to stop manufacturing GLUCAGON (Glucagon for injection, rDNA origin) and our GLUCAGON Emergency Kit globally due to decreased demand and to streamline our manufacturing processes.

Lilly is working to notify physicians, healthcare providers, hospitals, pharmacies, and wholesalers of the discontinuation timeline, to allow sufficient time to evaluate alternative glucagon options and to transfer these patients to alternate forms of treatment.

We currently anticipate the last distribution of GLUCAGON (Glucagon for injection, rDNA origin) from Lilly to pharmacy distributors in Canada will occur in approximately June 2023. Although this is the anticipated last date of distribution, GLUCAGON may be used until the expiry date on the product.

Information on the GLUCAGON withdrawal is posted on the Health Canada Drug Shortage website Drug shortages homepage ( Please find a link to the GLUCAGON Product Monograph here.

Please note that Lilly’s nasal glucagon product will remain available in Canada for the treatment of severe hypoglycemia in insulin treated people (aged 4 years and older) with diabetes mellitus, when impaired consciousness precludes oral carbohydrates.

For additional information, Lilly is available to answer your questions at our Customer Response Centre 1-888-545-5972 from 9 am – 5 pm Eastern Time, Monday through Friday.


External Affairs Contact:
Ethan Pigott